Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland)
Source: International Congress 2019 – Clinical studies of asthma treatments
Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2539
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland). Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma. 2539
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Improvement of the length tension relation in severe COPD with vilanterol trifenatate/fluticasone furoate Source: International Congress 2017 – Management of COPD Year: 2017
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2 -agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Inhaled vilanterol trifenatate/fluticasone furoate (VFF) improves respiratory muscle function and walking performance in severe COPD without change in pulmonary function Source: International Congress 2017 – Management of COPD Year: 2017
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Additive effect of Zafirlukast in combination with Mometason furoate in treatment of Nasal polyps in patients with mild persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003
Lung function and symptom improvements with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006